Claudia Gore

Claudia Gore

Auto-generated profile, based on publicly available information

Claudia Gore

Section of Inflammation, Repair and Development, National Heart & Lung Institute Imperial College London London UK

Research Focus & Metrics

Academic Career Length

16Years (2011-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
18 October 2011 in Clinical & Experimental Allergy
Verified
Journal Article
Closed access
PDF file
CGC. Gore
C. Gore
ACA. Custovic
A. Custovic
GTG. W. Tannock
G. W. Tannock
KMK. Munro
K. Munro
GKG. Kerry
G. Kerry
AWA. Woodcock
A. Woodcock

18 October 2022 in Allergy
Verified
Journal Article
Open access
MVMarta Vazquez‐Ortiz
Marta Vazquez‐Ortiz
CGClaudia Gore
Claudia Gore
CACherry Alviani
Cherry Alviani
EAElizabeth Angier
Elizabeth Angier
KBKatharina Blumchen
Katharina Blumchen
GRGraham Roberts
Graham Roberts
Introduction: Adolescence is a critical stage of rapid biological, emotional and social change and development. Adolescents and young adults (AYA) with asthma and allergies need to develop the knowledge and skills to self‐manage their health independently. Healthcare professionals (HCP), parents and their wider network play an essential role in supporting AYA in this process. Previous work showed significant limitations in transition care across Europe. In 2020, the first evidence‐based guideline on effective transition for AYA with asthma and allergies was published by EAACI.Aim: We herein summarize practical resources to support this guideline's implementation in clinical practice.Methods: For this purpose, multi‐stakeholder Task Force members searched for resources in peer review journals and grey literature. These resources were included if relevant and of good quality and were pragmatically rated for their evidence‐basis and user friendliness.Results: Resources identified covered a range of topics and targeted healthcare professionals, AYA, parents/carers, schools, workplace and wider community. Most resources were in English, web‐based and had limited evidence‐basis.Conclusions: This position paper provides a valuable selection of practical resources for all stakeholders to support effective transitional care for AYA with asthma and allergies. Future research should focus on developing validated, patient‐centred tools to further assist evidence‐based transition care.

26 September 2021 in Allergy
Verified
Journal Article
Closed access
PDF file
EKEkaterina Khaleva
Ekaterina Khaleva
Rebecca KnibbRebecca Knibb
Rebecca Knibb
ADAudrey DunnGalvin
Audrey DunnGalvin
MVMarta Vazquez‐Ortiz
Marta Vazquez‐Ortiz
Pasquale ComberiatiPasquale Comberiati
Pasquale Comberiati
GRGraham Roberts
Graham Roberts

13 March 2018 in Clinical & Experimental Allergy
Verified
Journal Article
Open access
PDF file
CGClaudia Gore
Claudia Gore
RGRobin B. Gore
Robin B. Gore
SFSara Fontanella
Sara Fontanella
SHSadia Haider
Sadia Haider
ACAdnan Custovic
Adnan Custovic
Summary: Background: Children with severe, persistent atopic eczema (AE) have limited treatment options, often requiring systemic immunosuppression.Objective: To evaluate the effect of the temperature‐controlled laminar airflow (TLA) treatment in children/adolescents with severe AE.Methods: We recruited 15 children aged 2‐16 years with long‐standing, severe AE and sensitization to ≥1 perennial inhalant allergen. Run‐in period of 6‐10 weeks (3 visits) was followed by 12‐month treatment with overnight TLA (Airsonett®, Sweden). The primary outcome was eczema severity (SCORAD‐Index and Investigator Global Assessment‐IGA). Secondary outcomes included child/family dermatology quality of life and family impact questionnaires (CDQLI, FDQLI, DFI), patient‐oriented eczema measure (POEM), medication requirements and healthcare contacts. The study is registered as ISRCTN65865773.Results: There was a significant reduction in AE severity ascertained by SCORAD and IGA during the 12‐month intervention period (P < .001). SCORAD was reduced from a median of 34.9 [interquartile range 28.75‐45.15] at Baseline to 17.2 [12.95‐32.3] at the final visit, and IGA improved significantly from 4 [3‐4] to 2 [1‐3]. We observed a significant improvement in FDQLI (16.0 [12.25‐19.0] to 12 [8‐18], P = .023) and DFI (P = .011), but not CDQLI or POEM. Compared to 6‐month period prior to enrolment, there was a significant reduction at six months after the start of the intervention in potent topical corticosteroids (P = .033). The exploratory cluster analysis revealed two strongly divergent patterns of response, with 9 patients classified as responders, and 6 as non‐responders.Conclusion and Clinical Relevance: Addition of TLA device to standard pharmacological treatment may be an effective add‐on to the management of difficult‐to‐control AE.

29 December 2020 in Skin Health and Disease
Verified
Journal Article
Open access
PDF file
FWF. Wilson
F. Wilson
EHE. Harnik
E. Harnik
CGC. Gore
C. Gore
Objectives In the United Kingdom, atopic dermatitis (AD) affects 20% of children and topical corticosteroids (TCS) are a mainstay of AD treatment regimes. Many TCS have similar packaging despite significant differences in potency frequently leading to confusion, and along with misinformation and steroid phobia, potentially reducing treatment adherence. We aimed to evaluate parents' knowledge/concerns regarding TCS and explore benefits of/preference for a TCS‐labelling system. Method Hundred parents of children with AD attending paediatric dermatology and/or allergy appointments completed mixed‐methodology Survey 1 (knowledge‐quiz, TCS‐labelling options, feedback on what supports AD‐care). Thirty parents, adolescents, and healthcare professionals completed Survey 2. Qualitative/quantitative data was thematically/statistically analysed (SPSS v25) respectively. Results Parents preferred the traffic light system (green = mild, yellow = moderate, red = potent; n = 71/100) and reported significantly increased willingness and comfort in using TCS if a labelling system was used p ≤ 0.001). Knowledge regarding TCS potency was lacking: 62% (n = 46/74) of mild TCS‐users overestimated potency; 51% (n = 67/131) of potent TCS‐users underestimated potency. Common concerns were TCS‐related skin thinning, long‐term side effects and themes for improved AD‐care/support included: better information, written plans, access to advice, involvement of certain staff. Parents wanted accessible information in various formats: verbally, electronic resources, leaflets, and education sessions. Conclusions Parents of children with AD confirmed significant concerns and demonstrated poor knowledge regarding TCS use. Our findings suggest that a simple labelling system may improve TCS adherence. Future work to test refined label prototypes and evaluating their impact on adherence and correct use is needed.

29 May 2023 in Clinical & Experimental Allergy
Verified
Journal Article
Open access
CGClaudia Gore
Claudia Gore
EMEleanor Minshall
Eleanor Minshall
LMLuise V. Marino
Luise V. Marino
HCHelen Cox
Helen Cox